Drug · DIN 02018993
STREPTASE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since February 22, 2012; first marketed December 31, 1994.
- Drug Identification Number (DIN)
- 02018993
- Company (DIN owner)
- Csl Behring Canada IncOttawa, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Powder For Solution
- Route
- Intravenous; Intracoronary
- Therapeutic class (ATC)
- Streptokinase B01AD01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| STREPTOKINASE | 250000 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 30, 2007: NOC 8682New Drug Submission (NDS) · Manufacturer name change
- February 16, 2005: NOC 6280New Drug Submission (NDS) · Manufacturer name change
- June 4, 2002: NOC 895New Drug Submission (NDS) · Manufacturer name change
- January 11, 2001: NOC 2596New Drug Submission (NDS) · Manufacturer name change
- October 5, 1994: NOC 5505Supplement to a New Drug Submission (SNDS) · Change in manufacturing
Other DINs named STREPTASE
- DIN 02019000 · Cancelled Post Market
- DIN 02019019 · Cancelled Post Market